Day: July 15, 2025

NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) — ExlService Holdings, Inc. (NASDAQ: EXLS), a global data and AI company, will release financial results for the second quarter ended June 30, 2025, on Tuesday, July 29, 2025, after the market closes. An earnings news release, investor fact sheet and presentation will be published on the company’s investor relations website offering an overview of the financial results. The company will host a conference call at 10:00 a.m. EDT the following day, Wednesday, July 30, 2025, with Chairman and Chief Executive Officer Rohit Kapoor and Executive Vice President and Chief Financial Officer Maurizio Nicolelli, who will provide insights into the company’s operational and financial results. To listen to video live webcast or to participate in the call, please register here. A replay of the webcast will...

COCONUT CREEK, Fla., July 15, 2025 (GLOBE NEWSWIRE) — Willis Lease Finance Corporation (NASDAQ: WLFC) (the “Company”), the leading lessor of commercial aircraft engines and global provider of aviation services, today announced it will release its financial results for the second quarter of 2025 before the market opens on August 5, 2025. The Company will host a conference call led by the executive management team that day at 10:00 a.m. Eastern Time. To participate in the conference call, please use the following dial-in numbers: U.S. and Canada: +1 (800) 289-0459International: +1 (646) 828-8082Conference ID: 101023 A digital replay will be available two hours after the completion of the conference call. To access the replay, please visit our website at www.wlfc.global under the Investor Relations section for details. About Willis...

Company Advances its Progress toward FDA Premarket Approval Study for its Next Generation Colorectal Cancer Screening Product and Makes a Strategic Acquisition in the Field of Pancreatic Cancer Screening BERKELEY, Calif. and MAINZ, Germany, July 15, 2025 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today reviewed its major accomplishments of the first six months ending June 30, 2025, and provided a corporate update. The Company expects to release its half year financial results in September 2025. Key Highlights During First Half 2025Mainz Biomed launched eAArly DETECT 2, a US feasibility study to evaluate the Company’s next generation colorectal cancer (CRC) test, integrating its proprietary mRNA biomarkers,...

         TARPON SPRINGS, Fla., July 15, 2025 — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor, today announced the signing of a new commercial agreement with a non-disclosed EU-based biotechnology company. The agreement provides the partner with a non-exclusive global license to a range of selected proprietary Allarity DRP® algorithms in breast cancer, alongside laboratory services from Allarity’s Medical Laboratory in Denmark. Under the agreement, Allarity will supply advanced transcriptome analysis services to support the partner’s efforts to deliver precision oncology solutions in breast cancer. The deal also secures purchase commitments for Allarity’s laboratory services...

GRAND JUNCTION, Colo., July 15, 2025 (GLOBE NEWSWIRE) — ProStar Holdings Inc. (“ProStar®” or “the Company”) (TSXV: MAPS) (OTCQX: MAPPF) (FSE: 5D00), a world leader in Precision Mapping Solutions®, is pleased to announce that a State Department of Transportation (DOT) has entered into a formal contractual agreement to evaluate ProStar’s flagship solution, PointMan®, for state wide adoption. This latest engagement from another DOT marks a significant milestone as ProStar continues to drive digital transformation in the management of critical infrastructure. The DOT’s evaluation will focus on how PointMan streamlines operations, improves workflows, and enhances safety during construction and maintenance activities. “The adoption of PointMan by the Colorado Department of Transportation has already proven to be a success,” stated Page...

Raanana, Israel, July 15, 2025 (GLOBE NEWSWIRE) — Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced that it has received a notification letter from the Nasdaq Hearings Panel (the “Panel”) granting the Company’s request for the continued listing of its securities on the Nasdaq Capital Market. As previously reported by the Company on May 23, 2025, the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) issued a public interest determination under Listing Rule 5101, citing the Company’s issuance of securities in a private placement (the “Private Placement”) pursuant to the securities purchase agreement dated March 31, 2025, particularly the Series A warrants exercisable on an alternate...

SAN CARLOS, Calif., July 15, 2025 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Corleen Roche as Chief Financial Officer (CFO), effective August 6th, 2025. “I am pleased to welcome Corleen to Iovance at such an important stage in our first commercial launch,” said Frederick G. Vogt, Ph.D., J.D., Interim Chief Executive Officer, President and General Counsel. “Corleen’s experience in executive financial leadership roles and multiple product launches will be invaluable as we focus on growing revenue, managing our balance sheet and advancing our mission of developing and delivering novel therapies to patients...

GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, August 6, 2025, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2025. Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent’s website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call can be accessed from the Investors page of Emergent’s website. About Emergent BioSolutions At Emergent, our mission is to protect and save lives. For...

VIDAA announced that it will serve as the smart TV operating system for Vestel’s CTV OEM base, furthering Nexxen’s European CTV reach NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) — Nexxen International Ltd. (NASDAQ: NEXN) (“Nexxen” or the “Company”), a global, flexible advertising technology platform with deep expertise in data and advanced TV, today announced it anticipates benefitting from the announcement that Vestel recently entered a strategic partnership with VIDAA, the world’s second largest and fastest-growing smart TV platform. Nexxen has a strategic partnership with VIDAA, which is set to expire at the end of 2026, and currently holds an approximately 2.439% ownership stake in the smart TV platform. In May 2025, Nexxen signed a non-binding Memorandum of Understanding (“MOU”) with VIDAA, outlining the potential extension and...

– Lucile Packard Children’s Hospital Stanford is ready to accept patients for ZEVASKYN treatment – – Abeona Therapeutics® and Stanford Medicine conducted research collaboration for more than a decade, culminating in U.S. Food and Drug Administration (FDA) approval of ZEVASKYN in April 2025 – – ZEVASKYN is the only FDA-approved therapy to treat RDEB wounds with a single application – CLEVELAND, July 15, 2025 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of the newest Qualified Treatment Center (QTC) for FDA-approved ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. This first-of-its-kind therapy, an outcome of a decade of research by Abeona and two decades of research at Stanford Medicine, where the technology originated, will be used to...